Orchestra BioMed Holdings, Inc.
$4.35
▼
-1.61%
2026-04-21 08:34:01
www.orchestrabiomed.com
NGM: OBIO
Explore Orchestra BioMed Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$268.03 M
Current Price
$4.35
52W High / Low
$5.42 / $2.2
Stock P/E
—
Book Value
$0.94
Dividend Yield
—
ROCE
-52.8%
ROE
-1.09%
Face Value
—
EPS
$-1.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
86
Beta
0.6
Debt / Equity
25.17
Current Ratio
6.45
Quick Ratio
6.43
Forward P/E
-2.43
Price / Sales
7.22
Enterprise Value
$160.94 M
EV / EBITDA
-3.13
EV / Revenue
4.81
Rating
None
Target Price
$12.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 2. | Definium Therapeutics, Inc. | $23.18 | — | $2.26 B | — | -44.54% | -64.06% | $23.41 / $5.36 | $3.36 |
| 3. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 4. | Jaguar Health, Inc. | $0.41 | — | $5.34 M | — | -91.43% | -628.65% | $15.48 / $0.31 | $0.85 |
| 5. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 6. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 7. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 30.92 M | 0.86 M | 0.84 M | 0.87 M | 0.25 M | — |
| Operating Profit | 6.75 M | -20.31 M | -19.33 M | -18.92 M | -16.68 M | — |
| Net Profit | 6.25 M | -20.83 M | -19.36 M | -18.75 M | -16.16 M | — |
| EPS in Rs | 0.11 | -0.36 | -0.33 | -0.32 | -0.28 | -0.41 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 33.48 M | 2.64 M | 2.76 M | 3.53 M |
| Operating Profit | -51.81 M | -64.3 M | -51.51 M | -32.66 M |
| Net Profit | -52.7 M | -61.02 M | -49.12 M | -33.61 M |
| EPS in Rs | -0.9 | -1.04 | -0.84 | -0.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 114.86 M | 76.17 M | 95.21 M | 95.57 M |
| Total Liabilities | 61.29 M | 43.22 M | 27.17 M | 43.04 M |
| Equity | 53.57 M | 32.96 M | 68.04 M | 52.53 M |
| Current Assets | 107.91 M | 69.17 M | 89.11 M | 84.69 M |
| Current Liabilities | 16.74 M | 16.21 M | 11.21 M | 18.57 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -48.96 M | -50.56 M | -46.13 M | -29.29 M |
| Investing CF | -26.94 M | 13.09 M | 10.69 M | -64.12 M |
| Financing CF | 88.33 M | 29.17 M | 46.22 M | 103.26 M |
| Free CF | -49.45 M | -50.85 M | -46.2 M | -29.88 M |
| Capex | -0.49 M | -0.29 M | -0.08 M | -0.59 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -4.42% | -21.88% | — | — |
| Earnings Growth % | -24.23% | -46.16% | — | — |
| Profit Margin % | -2313.27% | -1779.71% | -951.26% | — |
| Operating Margin % | -2437.49% | -1866.16% | -924.34% | — |
| Gross Margin % | 92.27% | 93.26% | 94.03% | — |
| EBITDA Margin % | -2425.82% | -1855.76% | -918.06% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.